News | September 27, 2011

New Trial Finds CCTA Superior to MPI for ER Chest Pain Evaluation


September 27, 2011 — A study in the Sept. 27 issue of the Journal of the American College of Cardiology suggests that early coronary computed tomographic angiography (CCTA) is preferable to rest-stress myocardial perfusion imaging (MPI) when evaluating acute low-risk chest pain in the emergency department. The Society of Cardiovascular Computed Tomography conducted the study.

The Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment (CT-STAT) multi-center trial suggests CCTA is faster, more accurate and less costly than MPI.

The study, led by James A. Goldstein, M.D., and Gilbert L. Raff, M.D., of William Beaumont Hospital, Royal Oak, Mich., ran between June 2007 and November 2008. Low-risk patients were randomized to treatment via CCTA or MPI, and followed up over a period of six months.

The two treatments were analyzed primarily over the time taken to diagnose, and also compared over safety (no major adverse cardiac events in patients with normal index tests), and the cost of care to the emergency department.

The results found CCTA patients were diagnosed 54 percent faster than MPI patients, and the total costs of care were 38 percent lower with the CCTA group. This is significant, given that the cost of each MPI test itself was only slightly greater than the cost for each CCTA test.

 Major adverse cardiac events were no different for each diagnostic strategy. The CCTA patients were also exposed to less radiation than the MPI patients (11.5 mSv vs 12.8 mSv, p=0.02).

About 8 million patients in the United States require emergency department evaluation for acute chest pain annually. Currently, extensive testing is required to diagnose or rule out a heart attack in low risk patients without obvious signs. These trial results should have a huge impact in regards to selecting CCTA as a method that is both more efficient and cost-beneficial.

For more information: www.scct.org


Related Content

News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 8, 2024 — People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium ...

Home April 08, 2024
Home
Subscribe Now